Ani Pharmaceuticals (ANIP) Change in Account Payables (2012 - 2026)

Ani Pharmaceuticals (ANIP) has 15 years of Change in Account Payables data on file, last reported at $5.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables fell 3.44% year-over-year to $5.4 million; the trailing twelve-month figure through Mar 2026 stood at $15.0 million (up 372.19% YoY), and the FY2025 full-year result was $15.2 million, up 3064.09% from the prior year.
• Change in Account Payables grew to $5.4 million in Q1 2026, from -$7.2 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $13.8 million in Q3 2025 to a low of -$9.1 million in Q3 2022.
• A 5-year average of $2.0 million and a median of $3.1 million in 2025 frame the typical range for Change in Account Payables.
• Peak annual rise in Change in Account Payables reached 753.23% in 2022, while the deepest fall reached 602.32% in 2022.
• Tracing ANIP's Change in Account Payables over 5 years: stood at $10.1 million in 2022, then plunged by 72.38% to $2.8 million in 2023, then slumped by 345.36% to -$6.8 million in 2024, then slipped by 6.07% to -$7.2 million in 2025, then surged by 174.06% to $5.4 million in 2026.
• Business Quant data shows ANIP's Change in Account Payables at $5.4 million in Q1 2026, -$7.2 million in Q4 2025, and $13.8 million in Q3 2025.